About
About Innovent Biologics, Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), PEMAZYRE (pemigatinib), olverembatinib, Cyramza (ramucirumab), Retsevmo (selpercatinib), FUCASO (Equecabtagene Autoleucel), SINTBILO (tafolecimab injection), DUPERT (fulzerasib), DOVBLERON (taletrectinib adipate), Jaypirca (pirtobrutinib), limertinib, SYCUME (teprotumumab N01 injection), mazdutide, PECONDLE (picankibart injection), and TABOSUN(Ipilimumab N01 injection). In addition, it sells and distributes pharmaceutical products; and offers consultation and research and development services. The company was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Visit company website
5 years, 5 months ago
Innovent Biologics, Inc is currently in a long term uptrend where the price is trading 11.1% above its 200 day moving average.
From a valuation standpoint, the stock is 78.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.2.
Innovent Biologics, Inc's total revenue rose by 307.3% to $3B since the same quarter in the previous year.
Its net income has increased by 61.2% to $-390M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.6% to $-372M since the same quarter in the previous year.
Based on the above factors, Innovent Biologics, Inc gets an overall score of 5/5.